IsoRay (ISR) PT Set at $2.00 by Maxim Group

IsoRay (NYSEAMERICAN:ISR) has been given a $2.00 price target by analysts at Maxim Group in a research note issued to investors on Wednesday. The brokerage currently has a “buy” rating on the healthcare company’s stock. Maxim Group’s price objective would indicate a potential upside of 344.44% from the company’s previous close.

Shares of IsoRay (ISR) opened at $0.45 on Wednesday. The company has a market cap of $25.35, a P/E ratio of -4.09 and a beta of 1.11. IsoRay has a 1 year low of $0.38 and a 1 year high of $0.69.

IsoRay (NYSEAMERICAN:ISR) last released its quarterly earnings results on Thursday, February 8th. The healthcare company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The business had revenue of $1.54 million during the quarter. IsoRay had a negative net margin of 95.25% and a negative return on equity of 69.11%.

In other IsoRay news, VP Michael Krachon purchased 55,000 shares of the stock in a transaction dated Monday, November 20th. The shares were acquired at an average cost of $0.50 per share, for a total transaction of $27,500.00. Following the completion of the transaction, the vice president now directly owns 19,609 shares of the company’s stock, valued at $9,804.50. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders bought 62,440 shares of company stock worth $31,092 over the last quarter.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at

IsoRay Company Profile

IsoRay, Inc is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds.

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with's FREE daily email newsletter.

Leave a Reply